KFH - VALLEJO
1. Target Overview & Investment Thesis
KFH - VALLEJO is a 184-bed suburban community hospital in SOLANO, CA with $531.7M in net patient revenue and a 0.3% operating margin. The hospital serves a payer mix of 7.1% Medicare, 11.1% Medicaid, and 81.8% commercial.
Thesis: Undervalued. Our ML models identify $39.1M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 0.3% to 7.7% (+736bps).
| Net Revenue HCRIS | $531.7M |
| Current EBITDA COMPUTED | $1.8M |
| Operating Margin COMPUTED | 0.3% |
| Occupancy HCRIS | 53.1% |
| Revenue / Bed COMPUTED | $2.9M |
| Net-to-Gross HCRIS | 28.7% |
| Distress Probability ML | 45.9% |
2. Market Context & Competitive Position
CA has 414 Medicare-certified hospitals with a median operating margin of -4.9%. The target's margin of 0.3% places it above the state median. Among 216 size-comparable peers (92-368 beds), the median margin is -4.5%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (92-368), prioritizing same-state peers. 216 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| KFH - VALLEJO (Target) | CA | 184 | $531.7M | 0.3% |
| CITY OF HOPE NATIONAL MEDICAL | CA | 217 | $1.83B | -10.7% |
| CHILDRENS HOSPITAL OF ORANGE C | CA | 334 | $1.31B | 0.7% |
| KFH - SANTA CLARA | CA | 343 | $1.25B | 12.5% |
| KFH - ROSEVILLE | CA | 352 | $1.18B | 14.2% |
| KFH - OAKLAND | CA | 365 | $1.13B | -6.3% |
| KECK HOSPITAL OF USC | CA | 301 | $1.11B | -20.8% |
| SUTTER ROSEVILLE MEDICAL CENTE | CA | 318 | $1.07B | 12.1% |
| EISENHOWER MEDICAL CENTER | CA | 362 | $1.04B | -11.8% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $39.1M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $11.2M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $10.6M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $10.5M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $6.5M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $340K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $1.8M |
| + RCM Uplift | +$39.1M |
| Pro Forma EBITDA | $40.9M |
| Current Margin | 0.3% |
| Pro Forma Margin | 7.7% |
| WC Released (1x) | $20.4M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $2.8M | $403.3M | 145.04x | 170.6% |
| Base (11x exit) | 10.0x | 11.0x | $2.8M | $444.5M | 159.87x | 175.9% |
| Bull Case | 9.0x | 11.0x | $2.5M | $574.6M | 229.60x | 196.6% |
| Bull (12x exit) | 9.0x | 12.0x | $2.5M | $627.6M | 250.77x | 201.9% |
| Bear Case | 11.0x | 10.0x | $3.1M | $206.7M | 67.58x | 132.2% |
| Bear (11x exit) | 11.0x | 11.0x | $3.1M | $228.4M | 74.66x | 136.9% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Standard execution risk | RCM improvement requires management buy-in and 12-18 month implementation timeline |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 216 hospitals with 92-368 beds
- Same-state prioritization (n=217)
- Comp margins: P25=-17.5% / P50=-4.5% / P75=4.6%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.